Skip to main content

Squadron Capital Management LLC

13F filer · CIK 0002050709
Reported Aug 14, 2026
Net buyer this quarter
13F portfolio value$322MU.S. long equity reported on 13F
Positions3416 new · 12 closed
Net flow last quarter+$17.2MBuys minus sells
Top 10 positions weight66.2%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 202634 positions
RLMDRelmada Therapeutics, Inc.$50.9M15.78%6.89%-13.3%Q4 2025
CCCCC4 Therapeutics, Inc.$33.6M10.43%5.86%+220.0%Q1 2026
COGTCogent Biosciences, Inc.$33.5M10.39%0.50%+9.8%Q4 2025
KODKodiak Sciences Inc.$19.5M6.05%0.80%+31.6%Q4 2025
RLAYRelay Therapeutics, Inc.$18.1M5.63%0.44%+44.2%Q1 2026
ZNTLZentalis Pharmaceuticals, Inc.$17.9M5.57%5.16%+1.9%Q1 2026
EWTXEdgewise Therapeutics, Inc.$11.8M3.66%0.27%-17.1%Q4 2025
MAZEMaze Therapeutics, Inc.$10M3.10%0.60%+30.1%Q4 2025
IVAInventiva S.A.$9.2M2.86%1.26%+355.1%Q4 2025
ANLAdlai Nortye Ltd.$8.8M2.73%Not reported-39.6%Q1 2026
ELVNEnliven Therapeutics, Inc.$8.12M2.52%0.22%NewQ2 2026
PALIPalisade Bio, Inc.$6.27M1.95%1.73%Not reportedQ4 2025
IKTInhibikase Therapeutics, Inc.$6.09M1.89%2.27%-14.3%Q4 2025
ADAGAdagene Inc.$5.25M1.63%2.11%NewQ2 2026
FBRXForte Biosciences, Inc.$4.78M1.48%1.10%NewQ2 2026
IFRXInflaRx N.V.$4.48M1.39%2.77%NewQ2 2026
ASMBAssembly Biosciences, Inc.$4.4M1.36%0.81%NewQ2 2026
PMNProMIS Neurosciences Inc.$4.28M1.33%3.62%Not reportedQ1 2026
CTNMContineum Therapeutics, Inc.$4.26M1.32%1.13%NewQ2 2026
CMPSCOMPASS Pathways plc$4.25M1.32%0.22%Not reportedQ4 2025
DFTXDefinium Therapeutics, Inc.$4M1.24%0.06%NewQ2 2026
SLGLSol-Gel Technologies Ltd.$3.86M1.20%1.87%+67.7%Q1 2026
BIOABioAge Labs, Inc.$3.8M1.18%0.34%NewQ2 2026
SCYXScynexis Inc$3.08M0.96%7.61%-20.4%Q1 2026
PRQRProQR Therapeutics N.V.$2.81M0.87%1.43%NewQ2 2026
RZLTRezolute, Inc.$2.1M0.65%0.42%NewQ2 2026
LPCNLipocine Inc.$2.07M0.64%9.83%+80.0%Q4 2025
CUECue Biopharma, Inc.$1.58M0.49%0.96%NewQ2 2026
CALCCalciMedica, Inc.$1.28M0.40%4.05%NewQ2 2026
QNCXQuince Therapeutics, Inc.$734K0.23%3.97%NewQ2 2026
KTTAPasithea Therapeutics Corp.$515K0.16%2.99%-52.4%Q4 2025
INMInMed Pharmaceuticals Inc.$504K0.16%6.09%NewQ2 2026
NMRANeumora Therapeutics, Inc.$170K0.05%0.05%NewQ2 2026
NXTCNextCure, Inc.$103K0.03%1.58%-75.7%Q4 2025
Q1 2026Reported May 15, 202630 positions
RLMDRelmada Therapeutics, Inc.$59M21.61%8.08%+26.5%Q4 2025
COGTCogent Biosciences, Inc.$30.3M11.11%0.46%+1.0%Q4 2025
KALVKalVista Pharmaceuticals, Inc.$19.8M7.27%1.92%+40.7%Q4 2025
KODKodiak Sciences Inc.$14.5M5.31%0.61%+30.3%Q4 2025
ABVXAbivax S.A.$14.5M5.30%0.17%-10.3%Q4 2025
EWTXEdgewise Therapeutics, Inc.$11M4.04%0.33%Not reportedQ4 2025
NKTRNektar Therapeutics$8.99M3.30%0.61%NewQ1 2026
ANLAdlai Nortye Ltd.$8.76M3.21%Not reportedNewQ1 2026
ZNTLZentalis Pharmaceuticals, Inc.$8.5M3.11%5.10%NewQ1 2026
MAZEMaze Therapeutics, Inc.$7.69M2.82%0.52%-47.5%Q4 2025
SCYXScynexis Inc$6.98M2.56%12.26%NewQ1 2026
RLAYRelay Therapeutics, Inc.$6.69M2.45%0.36%NewQ1 2026
CCCCC4 Therapeutics, Inc.$5.92M2.17%2.16%NewQ1 2026
IKTInhibikase Therapeutics, Inc.$5.88M2.15%2.65%-17.2%Q4 2025
PALIPalisade Bio, Inc.$5.25M1.92%1.79%-33.3%Q4 2025
EPRXEupraxia Pharmaceuticals Inc.$4.92M1.80%1.31%+36.0%Q4 2025
GHRSGH Research PLC$4.57M1.67%0.52%+3.2%Q4 2025
PMNProMIS Neurosciences Inc.$4.13M1.51%3.62%NewQ1 2026
LPCNLipocine Inc.$3.6M1.32%6.02%-15.1%Q4 2025
IVAInventiva S.A.$2.97M1.09%0.28%+78.3%Q4 2025
ALXOAlx Oncology Holdings Inc$2.93M1.07%1.06%NewQ1 2026
CNTXContext Therapeutics Inc.$2.88M1.06%1.20%NewQ1 2026
NXTCNextCure, Inc.$2.83M1.04%7.35%+11.8%Q4 2025
SLGLSol-Gel Technologies Ltd.$2.46M0.90%1.11%NewQ1 2026
KTTAPasithea Therapeutics Corp.$1.56M0.57%8.42%Not reportedQ4 2025
TRAWTraws Pharma, Inc.$936K0.34%5.04%-28.3%Q4 2025
TXMDTherapeuticsMD, Inc.$849K0.31%3.63%NewQ1 2026
SPRBSpruce Biosciences, Inc.$797K0.29%0.89%-82.6%Q4 2025
HOWLWerewolf Therapeutics, Inc.$469K0.17%1.16%NewQ1 2026
NEUPNeuphoria Therapeutics Inc.$312K0.11%1.43%NewQ1 2026
Q4 2025Reported Feb 17, 202629 positions
RLMDRelmada Therapeutics, Inc.$32.4M13.71%9.14%NewQ4 2025
COGTCogent Biosciences, Inc.$27.7M11.74%0.48%NewQ4 2025
MAZEMaze Therapeutics, Inc.$20.3M8.60%0.99%NewQ4 2025
ABVXAbivax S.A.$19.6M8.29%0.18%NewQ4 2025
KALVKalVista Pharmaceuticals, Inc.$11.3M4.79%1.38%NewQ4 2025
PALIPalisade Bio, Inc.$10.6M4.48%2.82%NewQ4 2025
EWTXEdgewise Therapeutics, Inc.$8.69M3.68%0.33%NewQ4 2025
IKTInhibikase Therapeutics, Inc.$8.66M3.67%3.21%NewQ4 2025
KODKodiak Sciences Inc.$8.16M3.46%0.47%NewQ4 2025
TERNTerns Pharmaceuticals, Inc.$7.68M3.25%0.17%NewQ4 2025
TARSTarsus Pharmaceuticals, Inc.$6.55M2.78%0.19%NewQ4 2025
UPBUpstream Bio, Inc.$6.26M2.65%0.43%NewQ4 2025
SPRBSpruce Biosciences, Inc.$6.1M2.58%5.10%NewQ4 2025
XENEXenon Pharmaceuticals Inc.$4.73M2.00%0.13%NewQ4 2025
DBVTDBV Technologies S.A.$4.6M1.95%0.14%NewQ4 2025
HELPCybin Inc.$4.29M1.82%2.43%NewQ4 2025
LPCNLipocine Inc.$4.26M1.80%8.61%NewQ4 2025
BLTEBelite Bio, Inc$4.16M1.76%0.07%NewQ4 2025
GHRSGH Research PLC$4M1.70%0.51%NewQ4 2025
EPRXEupraxia Pharmaceuticals Inc.$3.78M1.60%0.96%NewQ4 2025
VTYXVentyx Biosciences, Inc.$3.7M1.57%0.57%NewQ4 2025
NXTCNextCure, Inc.$3.36M1.42%6.76%NewQ4 2025
WVEWave Life Sciences, Inc.$2.98M1.26%0.09%NewQ4 2025
KTTAPasithea Therapeutics Corp.$2.71M1.15%9.09%NewQ4 2025
CMPSCOMPASS Pathways plc$2.68M1.14%0.40%NewQ4 2025
AVTXAvalo Therapeutics, Inc.$2.36M1.00%0.70%NewQ4 2025
IVAInventiva S.A.$1.4M0.59%0.16%NewQ4 2025
TRAWTraws Pharma, Inc.$806K0.34%7.87%NewQ4 2025
CLYMClimb Bio, Inc.$400K0.17%0.21%NewQ4 2025
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.